Stellantis discontinues hydrogen fuel cell program and van production
Carmaker Stellantis said on Wednesday it would discontinue its hydrogen fuel cell technology program and no longer launch hydrogen-powered vehicles this year, raising questions about the future of hydrogen subsidiary Symbio.
The group said the decision was due to the limited availability of hydrogen refueling infrastructure, high capital requirements and the need for stronger purchase incentives for customers.
'The hydrogen market remains a niche segment, with no prospects of mid-term economic sustainability,' Jean-Philippe Imparato, chief operating officer for enlarged Europe, said in a statement.
Car parts suppliers Michelin MICP.PA and Forvia FRVIA.PA said Stellantis' decision came as a surprise and would have 'serious operational and financial consequences' for Symbio, a joint venture in which Stellantis acquired a stake in 2023.
Stellantis is its main customer, accounting for nearly 80% of Symbio's business volume, said Forvia.
'Michelin's primary concern lies with the impact this will have on Symbio's employees, both in France and abroad,' the tyremaker said in a statement.
Symbio employs more than 650 people, according to its website. It opened a gigafactory in eastern France in 2023 as well as a new site in California.
Stellantis said it has initiated discussions with Symbio shareholders to evaluate the current market consequences and to preserve the best interests of the joint venture, in line with their respective obligations.
Imparato said the automaker had to 'make clear and responsible choices to ensure our competitiveness and meet the expectations of our customers with our electric and hybrid passenger and light commercial vehicles offensive.'
The group said it did not anticipate the adoption of hydrogen cell vans before the end of the decade.
Serial production of Stellantis' new Pro One range was scheduled to start in the summer in Hordain, in France, and Gliwice, in Poland.
The decision will not affect staffing at Stellantis production sites, the group said. It said all research and development activities focused on the hydrogen technology would be redirected to other projects.
(Reporting by Giulia Segreti, additional reporting by by Mathias de Rozario in Gdansk and Dominique Patton in Paris; Editing by Cristina Carlevaro, Tomasz Janowski and Emelia Sithole-Matarise)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach
FY25 revenue up 14.3% YOY FY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continue FY25 operating expenses lower by 24.5% YOY Negative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9% Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic disease, and lifestyle management solutions for healthcare providers and consumers, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, "Fiscal 2025 has been another year of massive transformation for Biotricity. We've further utilized workflow automation, AI, and continued technological enhancements to drive substantial improvements in operational expenses, margin expansion, and revenue growth. This year, we demonstrated our ability to scale efficiently while maintaining high-quality service, bringing us to the doorstep of EBITDA breakeven and long-term profitability. The expansion of our Cardiac AI Cloud platform, supported by strategic partnerships with other industry leaders, showcases our commitment to revolutionizing medical diagnostics, chronic care management, and consumer healthcare. Leveraging over a trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability and growth, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Collaborative partnerships established during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America. Biotricity has also forged a strategic partnership focused on payor contracts for value based and managed care programs, both of which are new verticals for the Company. These developments underscore our dedication to advancing innovative, accessible, and high-quality cardiac care solutions." FY25 Financial Highlights Revenue increased 14.3% to $13.8 million compared with $12.1 million in FY24 Gross margin was 76.6% for the fiscal year ended March 31, 2025, as compared to 69.3% in FY24; this was the result of expansion in recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring cost structure. Net loss decreased 20% YOY to $11.9 million, or $0.56 per share, from a net loss of $14.9 million, or $1.66 per share, in FY24 Q4-FY25 Financial Highlights Revenue increased 16.5% to $3.7 million compared with $3.5 million in Q4 FY24 Gross margin was 80.4% for the three months ended March 31, 2025, as compared to 71.5% in the corresponding prior year quarter Net loss decreased 54% YOY to $2 million, or $0.08 per share, from a net loss of $4.4 million, or $0.47 per share, in Q4-FY24 Operating Highlights for FY25 FY25 recurring (TaaS) Technology Fees rose a robust 12% YOY to $12.6 million, representing over 10.5 times Device Sales revenue Company continues to maintain an impressive track record of customer retention, driven by high-quality customer and provider friendly support services, emphasis on accurate diagnostics, and user-friendly solutions. Developed a range of state-of-the-art products to service a total addressable market of $35 billion. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US Arrived at positive cash flows by growing subscription-based revenues, improving margins, and leveraging automation and experience to increase efficiencies of SG&A. Full details of the Company's financial results will be filed with the SEC on Form 10-K and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Friday July 18, 2025 at 4:45 p.m. ET to discuss its financial results for fiscal year 2025 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity Fourth Quarter and FY 2025 Financial Results and Business Update Call Date: Friday, July 18, 2025 Time: 4:45pm ET (1:45pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13754989 Expiration: Friday, August 1, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Year ended March 31, 2025 Year ended March 31, 2024 3 months ended March 31, 2025 3 months ended March 31, 2024 $ $ $ $ Net loss attributable to common stockholders (11,942,000) (14,928,960) (2,022,133) (4,400,104) Add: Provision for income taxes - - - - Interest expense 3,262,038 3,018,803 891,752 814,943 Accretion and amortization expenses 1,945,769 2,178,873 165,560 598,063 Preferred stock dividends 3,520,821 834,677 86,396 217,634 EBITDA (3,213,372) (8,896,607) (878,425) (2,769,464) Add (Less) Share based compensation (1) 1,420,121 1,025,930 1,247,319 481,275 Other (income)/loss (2) 78,569 102,607 (49,405) (16,334) Gain (loss) upon convertible promissory notes conversion and redemption (2) 141267 (18,539) (8,391) (3,259) Fair value change on derivative liabilities (2) 595,442 (9,777) 127,162 (253,791) Adjusted EBITDA (977,973) (7,796,386) 438,260 (2,561,573) Weighted average number of common shares outstanding 21,524,884 8,991,766 21,524,884 9,441,667 Adjusted Loss per Share, Basic and Diluted (0.045) (0.867) 0.017 (0.271) (1) Share based compensation is a non-cash item (2) These items relate to financing transactions and do not reflect the Company's core operating activities Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts
Globe and Mail
27 minutes ago
- Globe and Mail
Wall Street hangs near its record as PepsiCo and United Airlines offset drops for health care stocks
NEW YORK (AP) — Wall Street is hanging near its records on Thursday following some better-than-expected updates on the economy and a mixed set of profit reports from big U.S. companies. The S&P 500 was virtually unchanged in early trading and just a bit below its all-time high set a week before. The Dow Jones Industrial Average was up 105 points, or 0.2%, as of 9:35 a.m. Eastern time, and the Nasdaq composite was adding 0.1% to its record set the day before. Trading was calmer than Wednesday's, when President Donald Trump jolted financial markets by saying he had discussed the 'concept' of firing the chair of the Federal Reserve but was unlikely to do so. Such a move could help Wall Street get the lower interest rates it loves but would also risk a weakened Fed unable to make the unpopular moves needed to keep inflation under control. PepsiCo jumped 6.6% after delivering revenue and profit that topped Wall Street's expectations. The drink and snack giant stood by its financial forecasts given in April, which projected lower full-year profit than previous forecasts due to increased costs from tariffs and a pullback in consumer spending. United Airlines flew 6.4% higher after reporting a stronger profit for the latest quarter than analysts expected. It also said it's seen an acceleration in demand from customers that began in early July, and it's expecting less uncertainty about the economy to hurt its business in the second half of this year. Lucid Group's stock surged 25.3% after it said Uber is aiming to use 20,000 or more of its vehicles over six years in a robotaxi program. Using an autonomy system by Nuro, it expects to launch 'later next year in a major US city.' Uber, which plans to invest hundreds of millions of dollars in Lucid and Nuro, saw its stock edge down by 0.1%. A strong profit report from Taiwan Semiconductor Manufacturing Co. helped tech stocks, and its net income soared nearly 61% in the last quarter from a year earlier. The chip maker said it's seeing strong demand from artificial-intelligence and other customers, and its stock that trades in the United States rose 2.2%. On the losing side of Wall Street was Abbott, which fell 6.1% despite delivering results for the latest quarter that edged past analysts' expectations. The health care company cut the top end of its forecasted range for revenue growth over 2025. Elevance Health dropped 9.2% after reporting a weaker profit than analysts expected. It cut its forecast for profit in 2025 because of rising medical cost trends in its Affordable Care Act business, along with other factors. In the bond market, Treasury yields were mixed following several better-than-expected reports on the economy. One said that shoppers upped their spending at U.S. retailers by more last month than economists expected. Such spending, along with a relatively solid jobs market, has helped keep the U.S. economy out of a recession. A separate report said that fewer U.S. workers applied for unemployment benefits last week, which could be a signal of limited layoffs. A third suggested unexpectedly strong growth in manufacturing in the mid-Atlantic region. Such solid data could keep the Federal Reserve on pause when it comes to interest rates. The Fed has been keeping rates steady this year, after cutting them at the end of last year. The Fed's chair, Jerome Powell, has been insisting that he wants to wait for more data about how Trump's tariffs will affect the economy and inflation before the Fed makes its next move. That's because while lower interest rates could goose the economy and prices for investments, they would also give inflation more fuel when prices may already be starting to feel the upward effects of tariffs. Thursday's strong economic helped push the two-year Treasury yield, which closely tracks expectations for the Fed, up to 3.89% from 3.88% late Wednesday. Longer-term Treasury yields, though, eased a bit, and the 10-year yield edged down to 4.44% from 4.46%. The Fed has less influence over these yields, where investors in the bond market carry more sway. Bond investors had briefly driven longer-term yields higher on Wednesday, when fears were high that Trump may fire Powell. The president has been angrily calling for Powell to cut interest rates, and a less independent Fed may end up keeping short-term rates low in the near term and allowing inflation to run higher in future years. Longer-term yields then relaxed after Trump said he was unlikely to fire Powell. In stock markets abroad, indexes rose across much of Europe and Asia.
Globe and Mail
27 minutes ago
- Globe and Mail
Zacks Investment Ideas feature highlights: Alphabet, Meta Platforms, Tesla, Apple and Microsoft
For Immediate Release Chicago, IL – July 17, 2025– Today, Zacks Investment Ideas feature highlights Alphabet GOOGL, Meta Platforms META, Tesla TSLA, Apple AAPL and Microsoft MSFT. Google Goes Windsurfing in the AI War for Talent In a very agile, clever, and surprising move, Google's parent company Alphabet swept into the debris of OpenAI's bid for the AI coding startup Windsurf and came out with the latest and greatest of prize possessions: top talent. On Friday, I had just profiled "Zuck the Poacher" in my weekly dive into all-things AI about the Meta Platforms CEO's aggressive strategy of buying, bribing, and stealing AI talent anywhere he could. Just when we thought the primary battle was between Tesla 's Elon Musk and OpenAI's Sam Altman, Mark Zuckerberg not only has been poaching talent from competitors, he also made the first big "acquisition-hire" of the talent wars with the purchase of 49% of private Scale AI for $14.3 billion, as discussed here... The Week in AI: "All incumbents are gonna get nuked." Also on Friday, I did an interview with Bloomberg about how Apple 's Tim Cook should be following a similar strategy as Zuck... Apple: Investors Call for Big AI Acquisition As Shares Slump Hours later the story was breaking that Google pulled off their legal "coup." Goliath Outwits David: How Google Navigated the Windsurf Win Windsurf, an AI-native coding platform known for its leading edge in code generation and "agentic coding," became one of the most coveted startups in the race to build advanced developer AI tools. Its flagship products -- like Windsurf Editor -- were adopted by over a million developers and major enterprises, with annual recurring revenue surging from $40 million to $100 million. OpenAI initially entered talks to acquire Windsurf for around $3 billion. However, the deal stalled due to concerns from OpenAI's top financial backer, Microsoft, whose broad IP-sharing agreement would have given it access to Windsurf's technology -- a potential threat given Microsoft's investment in competing products like GitHub Copilot. As the drama ensued, Alphabet stepped in and struck a deal to hire Windsurf's founder and CEO, Varun Mohan, along with other key research and development team members, to join Google's DeepMind AI division. This deal also included a non-exclusive license for Google to use certain Windsurf technologies. According to CNBC, Google paid $2.4 billion as part of this arrangement. Inherit the Windsurf However, the story didn't end there. Just days after the deal with Google, Cognition AI, the company behind the AI coding agent Devin, announced that they had acquired the remainder of Windsurf. This acquisition included Windsurf's intellectual property, product, brand, and the rest of its employees. Essentially, Google secured key talent and a non-exclusive license to some technology, while Cognition AI acquired the company's core assets and the majority of its team. This series of events highlights the intense competition for talent and technology in the rapidly evolving AI coding space. When I first heard this story, I thought "Wow, it's almost like Cognition was a young step-child heir who accidentally benefited from a divorce." That's no slight to the Cognition team, since I know nothing about them. I'm just a student of inheritance, both financial and genetic, and so I cannot resist the opportunity to mention that this week marks the 100th anniversary of the infamous Scopes "Monkey" Trial in Dayton, Tennessee. According to paleoanthropologist John Hawks, "The 1925 'trial of the century' featured a real showdown: a final cross-examination of William Jennings Bryan by counsel for the defense Clarence Darrow." I saw Hawks speak in November at a human evolution event after having read his 2017 book with colleague Lee Berger Almost Human: The Astonishing Tale of Homo naledi and the Discovery That Changed Our Human Story. Hawks will be participating next week in the events marking the centennial of the trial in Dayton and he just published an essay with his observations about science then and now -- "the good, the bad, and the fake" as he writes. I responded to him on X about his announcement... "I recently watched both versions of Inherit the Wind (1960 with Spencer Tracey and 1999 w Jack Lemmon) and was in awe of just how good that screenplay is. Such a great microcosm of society, politics, and religion." Hawks replied... "You're so right. One of the neatest things is that the climactic cross-examination of Bryan by Darrow really happened, and the screenplay is remarkably like the trial transcript." I highly suggest watching either film, or both, this weekend. You will not be disappointed in the performances or the screenplay. How Google Won the Deal: Key Strategy & Tactics Okay, let's get back to the deal of the month in AI because it highlights the "war" going on during the early stages of the gen-AI and agentic-AI goldrush. Here are three "killer" moves by the old, but not tired, Goliath of the web. 1. Non-Acquisition "Acqui-hire" Strategy Structure: Rather than pursuing a full buyout, Google offered about $2.4 billion for a non-exclusive technology license and to hire key talent—including Windsurf CEO Varun Mohan, co-founder Douglas Chen, and several senior R&D staff. The majority of Windsurf's team remained independent, and Windsurf retained the right to license its technology to other firms. Speed & Timing: Once the OpenAI talks collapsed, Google moved rapidly. Within hours of OpenAI officially ending its exclusivity window, Google announced the agreement, effectively outmaneuvering its rivals. 2. Focused on Talent and Technology Leadership Acquisition: Google's DeepMind gained Windsurf's core technical leadership, who will focus on advancing agentic coding for the Gemini AI project—enabling AI systems that not only generate, but autonomously manage and improve, complex software. Technology Licensing: By securing a non-exclusive license, Google gains immediate and deep integration of Windsurf's proprietary AI coding tech into its Gemini and DeepMind platforms, accelerating internal innovation while avoiding regulatory scrutiny that a full acquisition might have invoked. 3. Capitalizing on Competitor Disarray OpenAI's Stumbling Block: IP access requirements demanded by Microsoft—OpenAI's largest backer—created internal friction and "deal fatigue," which led Windsurf to reject OpenAI's overtures. This made Google's less-intrusive, rapid approach more attractive to Windsurf's executives. Neutralizing Microsoft: By structuring the agreement as a talent and license deal, Google sidestepped IP clauses that could have benefitted Microsoft, keeping its competitive advantage intact. Big Benefits for Brin & Co. I've been talking a lot lately about an interview I saw with Google co-founder Sergey Brin and DeepMind founder Demis Hassibas. Brin essentially said that he came out of retirement to work at Google with Hassibas because he thought it was the most exciting time ever to be a computer scientist and he couldn't imagine any missing this opportunity. He also said, with conviction, that Gemini will be the first to AGI (artificial general intelligence), where the model can perform all human intelligence tasks. So what did they gain with the Windsurf win? The Windsurf acquisition was a strategic win for Google's AI ambitions because it allowed the company to rapidly strengthen its leadership in next-generation AI-powered coding tools and agentic AI systems Securing key individuals and technologically advanced code-generation capabilities positions Google as a leader in the next wave of AI for software development and agentic AI experiences. The non-exclusive license avoids excessive regulatory scrutiny and allows both Google and Windsurf to benefit from continued innovation and commercial partnerships. And for investors and analysts I think it adds renewed confidence to the "innovation commitment" for a company that needs to evolve beyond reliance on search-based advertising. Bottom line: This deal demonstrates the new reality of AI M&A strategy, where talent and rapid execution can matter just as much as traditional acquisitions in shaping the future of advanced technology platforms. BREAKING: As I write and we look forward to Alphabet's quarterly report in one week -- where we hope to learn more about leveraging the Windsurf "acqui-hire" -- the Goliath just announced $25 billion in additional investment in AI datacenters with a focus on energy infrastructure. Kevin Cook is a Senior Stock Strategist at Zacks Investment Research where he runs the TAZR Trader portfolio service and keeps his eyes on all-things AI in his multimedia program The Week In AI. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Tesla, Inc. (TSLA): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report
